Molecular Docking Study of Ferulic Acid Analog Compounds as Lung Antifibrotic at TGF-β1 Receptors
Downloads
Pulmonary fibrosis is one of the conditions that occur in Post-COVID Syndrome patients. Development of specific treatment as an agent to treat pulmonary fibrosis is still ongoing. Ferulic acid is a compound that has a potential lung antifibrotic agent through inhibition of TGF-β1-mediated signaling. Molecular docking studies using the AutoDock Tools program version 1.5.7 were conducted on ferulic acid and its analogs to determine the activity of compounds as antifibrotic. Furthermore, the interaction of the compound with the receptor was visualized using the Discovery Studio 2021 program. The results showed that ferulic acid and its analogs have lower free energy than pirphenidone which is a standard lung antifibrotic drug. 4- benzoyloxy-3-methoxycinnamic acid is the compound that has the greatest activity. The group that contributes to the ligand-receptor interaction is the aromatic group with π interaction.
Keywords: Molecular docking, AutoDock, antifibrotic, TGF-β1, ferulic acid
Ali, S.A., Saifi, M.A., Pulivendala, G., Godugu, C., Talla, V. (2021) Ferulic acid ameliorates the progression of pulmonary fibrosis via inhibition of TGF-β/smad signalling. Food and Chemical Toxicology, 149, 111980.
Burnham, E.L., Janssen, W.J., Riches, D.W.H., Moss, M., Downey, G.P. (2014) The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance, European Respiratory Journal, 43(1), 276–285.
Chaudhuri, D., Sasaki, K., Karkar, A., Sharif, S., Lewis, K., Mammen, M.J., Alexander, P., Ye, Z., Lozano, L.E.C., Munch, M.W., Perner, A., Du, B., Mbuagbaw, L., Alhazzani, W., Pastores, S.M., Marshall, J., Lamontagne, F., Annane, D., Meduri, G.U., Rochwerg, B. (2021) Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis, Intensive Care Medicine, 47(5), 521–537.
Dar, A.M., Mir, S. (2017) Molecular Docking: Approaches, Types, Applications and Basic Challenges, Journal of Analytical & Bioanalytical Techniques, 08(02).
Ekowati, J., Diyah, N.W., Nofianti, K.A., Hamid, I.S., Siswandono, S. (2018) Molecular Docking of Ferulic Acid Derivatives on P2Y12 Receptor and their ADMET Prediction, Journal of Mathematical and Fundamental Sciences, 50(2), 203–219.
Hoffmann-La Roche (2020) Multicenter, International, Double-blind, Two-Arm, Randomized, Placebo-controlled Phase II Trial of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing ILD, Clinical trial registration NCT03099187. clinicaltrials.gov, (Diakses: 27 December 2022).
Hama Amin, B.J., Kakamad, F.H., Ahmed, G.S., Ahmed, S.F., Abdulla, B.A., Mohammed, S.H., Mikael, T.M., Salih, R.Q., Ali, R. k., Salh, A.M., Hussein, D.A. (2022) Post COVID-19 pulmonary fibrosis; a meta-analysis study, Annals of Medicine and Surgery, 77, 103590.
Huey, R., Morris, G.M., Olson, A.J., Goodsell, D.S. (2007) A semiempirical free energy force field with charge-based desolvation, Journal of Computational Chemistry, 28(6), 1145–1152.
Maher, T.M., Bendstrup, E., Dron, L., Langley, J., Smith, G., Khalid, J.M., Patel, H., Kreuter, M. (2021) Global incidence and prevalence of idiopathic pulmonary fibrosis, Respiratory Research 22, 197.
Mancuso, C., Santangelo, R. (2014) Ferulic acid: Pharmacological and toxicological aspects, Food and Chemical Toxicology, 65, 185–195.
Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M.V., McGroder, C., Stevens, J.S., Cook, J.R., Nordvig, A.S., Shalev, D., Sehrawat, T.S., Ahluwalia, N., Bikdeli, B., Dietz, D., Der-Nigoghossian, C., Liyanage-Don, N., Rosner, G.F., Bernstein, E.J., Mohan, S., Beckley, A.A., Seres, D.S., Choueiri, T.K., Uriel, N., Ausiello, J.C., Accili, D., Freedberg, D.E., Baldwin, M., Schwartz, A., Brodie, D., Garcia, C.K., Elkind, M.S.V., Connors, J.M., Bilezikian, J.P., Landry, D.W., Wan, E.Y. (2021) Post-acute COVID-19 syndrome, Nature Medicine, 27(4), 601–615.
Prieto-Martínez, F.D., Arciniega, M., Medina-Franco, J.L., Prieto-Martínez, F.D., Arciniega, M., Medina-Franco, J.L. (2018) Molecular docking: current advances and challenges. TIP Rev. Espec. En Cienc, Quím.-Biológicas 21. https://doi.org/10.22201/ fesz.23958723e.2018.0.143
Sharif, R. (2017) Overview of idiopathic pulmonary fibrosis (IPF) and evidence-based guidelines, American Journal of Managed Care, 23(11 Suppl), S176–S182.
Siswandono, E. (2016) Kimia Medisinal 1 Edisi 2. Airlangga University Press.
Sriramulu, D.K., Wu, S., Sun-Gu, L. (2020) Effect of ligand torsion number on the AutoDock mediated prediction of protein-ligand binding affinity, Journal of Industrial and Engineering Chemistry, 83, 359–365.
Thannickal, V.J., Henke, C.A., Horowitz, J.C., Noble, P.W., Roman, J., Sime, P.J., Zhou, Y., Wells, R.G., White, E.S., Tschumperlin, D.J. (2014) Matrix Biology of Idiopathic Pulmonary Fibrosis: A Workshop Report of the National Heart, Lung, and Blood Institute. The American Journal of Pathology, 184(6), 1643–1651.
Vietri, L., Cameli, P., Perruzza, M., Cekorja, B., Bergantini, L., d’Alessandro, M., Refini, R.M., Pieroni, M., Fossi, A., Bennett, D., Spalletti, M., Mazzei, M.A., Sestini, P., Rottoli, P., Bargagli, E. (2020) Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral center of Siena, Therapeutic Advances in Respiratory Disease, 14.
Wei, P., Xie, Y., Abel, P.W., Huang, Y., Ma, Q., Li, L., Hao, J., Wolff, D.W., Wei, T., Tu, Y. (2019) Transforming growth factor (TGF)-β1-induced miR-133a inhibits myofibroblast differentiation and pulmonary fibrosis, Cell Death & Disease, 10(9), 1–17.
Zhao, Y., Shang, Y., Song, W., Li, Q., Xie, H., Xu, Q., Jia, J., Li, L., Mao, H., Zhou, X., Luo, H., Gao, Y., Xu, A. (2020) Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery, EClinical Medicine, 25, 100463
Copyright (c) 2023 Denayu Pebrianti, Juni Ekowati, Dhea Ananda Ainurrizma
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
BIKF by Unair is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under “the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
